OHSS
MCID: OVR029
MIFTS: 64

Ovarian Hyperstimulation Syndrome (OHSS)

Categories: Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Hyperstimulation Syndrome

MalaCards integrated aliases for Ovarian Hyperstimulation Syndrome:

Name: Ovarian Hyperstimulation Syndrome 58 12 60 76 38 30 13 56 6 45 15 41 74
Ohss 58 60 76
Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous 58
Secondary Meig's Syndrome 12

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant

Miscellaneous:
symptoms occur only during pregnancy (usual onset after 6 weeks gestation)
major fluid shifts may occur in severe cases


HPO:

33
ovarian hyperstimulation syndrome:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:5425
OMIM 58 608115
KEGG 38 H01039
MeSH 45 D016471
MESH via Orphanet 46 D016471
ICD10 via Orphanet 35 N98.1
UMLS via Orphanet 75 C0085083
Orphanet 60 ORPHA64739
MedGen 43 C0085083
UMLS 74 C0085083

Summaries for Ovarian Hyperstimulation Syndrome

UniProtKB/Swiss-Prot : 76 Ovarian hyperstimulation syndrome: Disorder which occurs either spontaneously or most often as an iatrogenic complication of ovarian stimulation treatments for in vitro fertilization. The clinical manifestations vary from abdominal distention and discomfort to potentially life-threatening, massive ovarian enlargement and capillary leak with fluid sequestration. Pathologic features of this syndrome include the presence of multiple serous and hemorrhagic follicular cysts lined by luteinized cells, a condition called hyperreactio luteinalis.

MalaCards based summary : Ovarian Hyperstimulation Syndrome, also known as ohss, is related to ectopic pregnancy and polycystic ovary syndrome, and has symptoms including vomiting, abdominal pain and nausea. An important gene associated with Ovarian Hyperstimulation Syndrome is FSHR (Follicle Stimulating Hormone Receptor), and among its related pathways/superpathways are Neuroactive ligand-receptor interaction and Development Endothelin-1/EDNRA signaling. The drugs Ganirelix and Metformin have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and pituitary, and related phenotypes are ascites and abdominal pain

Disease Ontology : 12 An ovarian disease that is characterized by cystic enlargement of the ovaries and a fluid shift from the intravascular to the third space and has symptom abdominal pain, has symptom nausea and has symptom vomiting. This disease is an iatrogenic complication of assisted reproduction technology.

Wikipedia : 77 Ovarian hyperstimulation syndrome (OHSS) is a medical condition that can occur in some women who take... more...

Description from OMIM: 608115

Related Diseases for Ovarian Hyperstimulation Syndrome

Diseases related to Ovarian Hyperstimulation Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 138)
# Related Disease Score Top Affiliating Genes
1 ectopic pregnancy 30.9 CGA GNRH1 VEGFA
2 polycystic ovary syndrome 30.7 CYP19A1 FSHR GNRH1
3 retinal artery occlusion 30.2 F5 VEGFA
4 anuria 30.1 ALB REN
5 endometriosis 29.7 CYP19A1 GNRH1 VEGFA
6 infertility 29.3 CYP19A1 FSHR GNRH1 LHCGR
7 myocardial infarction 29.2 ALB CDH5 F5 REN VEGFA
8 ovarian disease 27.8 AMH CGA CYP19A1 FSHR GNRH1 LHCGR
9 capillary leak syndrome 11.3
10 thrombosis 10.7
11 hypothyroidism 10.4
12 hypogonadotropic hypogonadism 23 without anosmia 10.4 FSHR GNRH1
13 severe nonproliferative diabetic retinopathy 10.3 ALB VEGFA
14 thrombophilia due to thrombin defect 10.3
15 adenoma 10.3
16 acroosteolysis 10.3 ALB VEGFA
17 hydrocele 10.3 CGA VEGFA
18 background diabetic retinopathy 10.3 ALB VEGFA
19 angiokeratoma circumscriptum 10.3 KDR VEGFA
20 hypertensive nephropathy 10.3 ALB VEGFA
21 thrombophilia 10.3
22 ovarian cyst 10.3
23 gastric lymphoma 10.3 ALB VEGFA
24 skin hemangioma 10.3 KDR VEGFA
25 radiation proctitis 10.3 KDR VEGFA
26 epithelioid hemangioendothelioma 10.3 KDR VEGFA
27 capillary hemangioma 10.3 KDR VEGFA
28 ischemic colitis 10.3 F5 VEGFA
29 nodular prostate 10.3 GNRH1 KDR
30 angiomatous meningioma 10.3 KDR VEGFA
31 pituitary adenoma 10.3
32 peritonitis 10.3
33 leydig cell hypoplasia 10.3 CGA LHCGR
34 leukostasis 10.2 KDR VEGFA
35 retinal vascular occlusion 10.2 F5 VEGFA
36 lymphangioma 10.2 KDR VEGFA
37 central retinal vein occlusion 10.2 F5 VEGFA
38 hydrops, lactic acidosis, and sideroblastic anemia 10.2 ALB VEGFA
39 freemartinism 10.2 AMH GNRH1
40 breast cancer 10.2
41 respiratory failure 10.2
42 pulmonary edema 10.2
43 functioning gonadotropic adenoma 10.2
44 coats disease 10.2 KDR VEGFA
45 premature menopause 10.2 AMH GNRH1
46 benign essential hypertension 10.2 ALB REN
47 kidney papillary necrosis 10.2 ALB REN
48 retinal vascular disease 10.2 ALB KDR VEGFA
49 orthostatic proteinuria 10.2 ALB REN
50 microvascular complications of diabetes 5 10.1 ALB KDR VEGFA

Graphical network of the top 20 diseases related to Ovarian Hyperstimulation Syndrome:



Diseases related to Ovarian Hyperstimulation Syndrome

Symptoms & Phenotypes for Ovarian Hyperstimulation Syndrome

Human phenotypes related to Ovarian Hyperstimulation Syndrome:

60 33 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ascites 60 33 hallmark (90%) Very frequent (99-80%) HP:0001541
2 abdominal pain 60 33 hallmark (90%) Very frequent (99-80%) HP:0002027
3 increased circulating gonadotropin level 60 33 hallmark (90%) Very frequent (99-80%) HP:0000837
4 enlarged polycystic ovaries 60 33 hallmark (90%) Very frequent (99-80%) HP:0008675
5 abdominal distention 60 33 hallmark (90%) Very frequent (99-80%) HP:0003270
6 increased serum testosterone level 60 33 hallmark (90%) Very frequent (99-80%) HP:0030088
7 nausea 60 33 hallmark (90%) Very frequent (99-80%) HP:0002018
8 hirsutism 60 33 hallmark (90%) Very frequent (99-80%) HP:0001007
9 capillary leak 60 33 hallmark (90%) Very frequent (99-80%) HP:0030005
10 pleural effusion 60 33 frequent (33%) Frequent (79-30%) HP:0002202
11 hemorrhagic ovarian cyst 60 33 frequent (33%) Frequent (79-30%) HP:0012886
12 hypovolemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0011106
13 peripheral edema 60 33 occasional (7.5%) Occasional (29-5%) HP:0012398
14 generalized edema 60 33 occasional (7.5%) Occasional (29-5%) HP:0007430
15 pulmonary edema 60 33 occasional (7.5%) Occasional (29-5%) HP:0100598
16 nausea and vomiting 60 Very frequent (99-80%)
17 abnormality of the genitourinary system 33 HP:0000119
18 ovarian cyst 60 Frequent (79-30%)

Symptoms via clinical synopsis from OMIM:

58
Abdomen:
ascites
abdominal pain

Genitourinary Internal Genitalia Female:
enlarged multilocular ovaries
pathology shows multiple serous and hemorrhagic follicular cysts lined by luteinized cells ('hyperreactio luteinalis')
ovaries return to normal size after delivery

Abdomen Gastrointestinal:
nausea

Clinical features from OMIM:

608115

Symptoms:

12
  • vomiting
  • abdominal pain
  • nausea

UMLS symptoms related to Ovarian Hyperstimulation Syndrome:


abdominal pain, nausea

MGI Mouse Phenotypes related to Ovarian Hyperstimulation Syndrome:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.23 ALB AMH CDH5 CGA CYP19A1 F5
2 growth/size/body region MP:0005378 10.19 CDH5 CGA CYP19A1 F5 FSHR GNRH1
3 endocrine/exocrine gland MP:0005379 10.16 ALB AMH CDH5 CGA CYP19A1 FSHR
4 cardiovascular system MP:0005385 10.13 CDH5 CYP19A1 F5 FSHR KDR LHCGR
5 hematopoietic system MP:0005397 10.08 CDH5 CYP19A1 FSHR GNRH1 KDR LHCGR
6 immune system MP:0005387 10.03 CDH5 CYP19A1 FSHR GNRH1 KDR LHCGR
7 liver/biliary system MP:0005370 9.97 ALB CDH5 CYP19A1 F5 GNRH1 KDR
8 integument MP:0010771 9.95 CDH5 CYP19A1 F5 FSHR GNRH1 KDR
9 nervous system MP:0003631 9.91 CGA CYP19A1 F5 FSHR GNRH1 KDR
10 neoplasm MP:0002006 9.72 ALB AMH FSHR GNRH1 VEGFA
11 normal MP:0002873 9.7 ALB CDH5 CYP19A1 GNRH1 KDR REN
12 renal/urinary system MP:0005367 9.43 ALB CYP19A1 GNRH1 LHCGR REN VEGFA
13 reproductive system MP:0005389 9.28 AMH CDH5 CGA CYP19A1 FSHR GNRH1

Drugs & Therapeutics for Ovarian Hyperstimulation Syndrome

Drugs for Ovarian Hyperstimulation Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ganirelix Approved Phase 4,Phase 3,Phase 2,Not Applicable 124904-93-4, 123246-29-7 25081094
2
Metformin Approved Phase 4,Not Applicable 657-24-9 14219 4091
3
Sodium Citrate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 68-04-2
4
Cetrorelix Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 120287-85-6 25074887 16129715
5
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Not Applicable 28014-46-2
6
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112809-51-5 3902
7
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-28-2 5757
8
Leuprolide Approved, Investigational Phase 4,Phase 3 53714-56-0 657181 3911
9
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 57-83-0 5994
10
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 62-31-7, 51-61-6 681
11
Cabergoline Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 81409-90-7 54746
12
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
13
Nafarelin Approved Phase 4 76932-56-4 25077649 16129618
14
Menotropins Approved Phase 4,Phase 3,Not Applicable 9002-68-0, 61489-71-2 5360545
15
Buserelin Approved, Investigational Phase 4 57982-77-1
16
Estrone Approved Phase 4 53-16-7 5870
17
leucovorin Approved Phase 4,Phase 3 58-05-9 143 6006
18
Dalteparin Approved Phase 4 9005-49-6
19
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
20
Enoxaparin Approved Phase 4 9005-49-6 772
21
Norgestrel Approved Phase 4 6533-00-2 13109
22
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
23
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
24
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 77-92-9 311
25
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 7440-70-2 271
26
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
28 Deslorelin Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 57773-65-6
29
Enclomiphene Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15690-57-0
30 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Contraceptive Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Triptorelin Pamoate Phase 4,Phase 3,Phase 2,Not Applicable
35 Luteolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
36 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Hypoglycemic Agents Phase 4,Not Applicable
38 Prolactin Release-Inhibiting Factors Phase 4,Phase 2,Phase 3,Not Applicable
39 Zuclomiphene Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Citrate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Clomiphene Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Chorionic Gonadotropin Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
43 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Not Applicable
47 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Not Applicable
48 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 201)
# Name Status NCT ID Phase Drugs
1 Corifollitropin Alfa Application in PCOS Patients Unknown status NCT02215135 Phase 4 Corifollitropin alfa
2 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
3 Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVF Unknown status NCT01438190 Phase 4 Metformin, gonadotropins in step-down regimen;Placebo, gonadotropins in step-up regimen
4 Comparing Coasting by Withholding GnRH Agonist With GnRH Antagonist Unknown status NCT01347268 Phase 4
5 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
6 Type of Gonadotropin and Embryo Kinetics of Development Unknown status NCT02402192 Phase 4 Corifollitropin alfa
7 Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders Unknown status NCT01926210 Phase 4
8 Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS Completed NCT02670304 Phase 4 letrozole;Aspirin
9 Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS Completed NCT01815138 Phase 4 hCG;hCG
10 The Use of GnRH Agonist Trigger in the Prevention of OHSS Completed NCT00349258 Phase 4 Leuprolide acetate
11 Endometrial Receptivity After GnRH Agonist Triggering Completed NCT01500863 Phase 4 hCG;triptorelin;Triptorelin, estradiol valerate, micronized vaginal progesterone;triptorelin, hCG;triptorelin, hCG;triptorelin, recombinant LH
12 Short Versus Long Protocol for IVF and IVF+ICSI Completed NCT00756028 Phase 4 Patients receiving short protocol IVF/ICSI-treatment.;Long protocol
13 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS) Completed NCT00805935 Phase 4 Menotropin;Progesterone vaginal insert;Follitropin beta;Progesterone in oil;leuprolide acetate
14 Endometrial Advancement After Rec or u-HCG Triggering Completed NCT00953628 Phase 4 10000 IU urinary HCG;250 mcg recombinant HCG
15 Anti-Mullerian Hormone (AMH) Versus Antral Follicle Count (AFC) Guided rFSH Dosing Study Completed NCT01783301 Phase 4 FSH
16 The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation Completed NCT01065376 Phase 4
17 Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles Completed NCT01233206 Phase 4 Metformin;Placebo administration
18 COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation Completed NCT02288143 Phase 4 COOL-COS
19 Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction Completed NCT01081626 Phase 4 Recombinant FSH (follitropin alpha)
20 Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles Completed NCT00627406 Phase 4 Buserelin and Pregnyl;Pregnyl;Buserelin and Pregnyl;Pregnyl
21 Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI Completed NCT03118830 Phase 4 Triptorelin;cetrorelix;Recombinant Follicle Stimulating Hormone
22 Follicular Steroid Genesis in Controlled Ovarian Stimulation Completed NCT02738580 Phase 4 COS with GnRH antagonists and rFSH;COS with GnRH antagonists and HP-HMG
23 FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST) Completed NCT01969201 Phase 4 Urofollitrophin;Follitrophin alpha
24 Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist Completed NCT01607203 Phase 4 Decapeptyl Daily;pregnyl
25 MENOPUR® Versus FOLLISTIM® Completed NCT00802360 Phase 4 Menotropin;Progestrone vaginal insert;follitropin beta;Progesterone in oil;Ganirelix
26 Menopur Mixed Protocol Completed NCT01417195 Phase 4 Bravelle;Menopur
27 Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients Completed NCT02466204 Phase 4 corifollitropin alfa;Follitropin Beta
28 Luteal Phase FSH in the IVF Poor Responder Completed NCT00225433 Phase 4 follitropin beta;ganirelix acetate
29 The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis Completed NCT01581359 Phase 4 Triptorelin acetate
30 Preventive Application of GnRH Antagonist on Early OHSS Recruiting NCT03188471 Phase 4 GnRH antagonist;aspirin
31 Hormone Evaluation in Artificial Reproductive Technology Recruiting NCT03737253 Phase 4 Follitropin alpha;Menotropin
32 Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration Recruiting NCT02330770 Phase 4 GnRHa and HCG;GnRHa then HCG (single low-dose);GnRHa then HCG (multiple low-doses)
33 Effects of Clomiphene Citrate Ovulation Induction on Frozen Embryo Transfer Recruiting NCT03309436 Phase 4 Clomiphene Citrate protocol
34 Efficacy and Safety of Medication Used to Stimulate Ovulation Recruiting NCT02715336 Phase 4 Ovulation induction with hCG and Lupron (GnRH agonist)
35 Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS Recruiting NCT02436226 Phase 4 Clomiphene citrate and Human chorionic gonadotropin (HCG);Clomiphene citrate
36 Gonapure® in Multifollicular Stimulation in Egyptian Women Undergoing IVF/ICSI Recruiting NCT03057574 Phase 4 Follitropin Alfa
37 Cetrorelix and Ganirelix Flexible Protocol for (IVF) Recruiting NCT03477929 Phase 4 Ganirelix Acetate;Cetrorelix Acetate
38 Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders Recruiting NCT03177538 Phase 4 Corifollitropin alfa and menotropin;Follitropin alfa and lutropin alfa
39 NATural Ovarian Stimulation Active, not recruiting NCT02892942 Phase 4 Gonal-F®;Cetrotide®;Cetrotide®
40 The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation Not yet recruiting NCT03809221 Phase 4 Triptorelin acetate
41 Effect of LMWH on Pregnancy Outcome in Women With Multiple Failures of IVF-ET Not yet recruiting NCT03701750 Phase 4 Low Molecular Weight Heparin (enoxaparin sodium)
42 Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome? Terminated NCT01714648 Phase 4 Triptorelin 0.2 mg
43 Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation Terminated NCT01606709 Phase 4 GnRH agonist;hCG
44 Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF) Terminated NCT02221154 Phase 4
45 Low-dose Gonal-f® in Ovulation Induction Terminated NCT01871532 Phase 4 Gonal-f®
46 Metformin in Assisted Reproduction-MET-AR-study Terminated NCT00159575 Phase 4 Metformin / Placebo treatment for 4 months
47 Pituitary Down-regulation Before IVF for Women With Endometriosis Terminated NCT01757249 Phase 4 Combined Oral Contraceptive Pill (Microgynon 30)
48 Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles? Withdrawn NCT00804960 Phase 4 Letrozole;Std IVF Protocol
49 IVF Versus Gonadotropin Therapy in Women With CC Resistant PCOS Withdrawn NCT02458963 Phase 4 Gonadotropin
50 IVF Versus LOD in Women With CC Resistant PCOS Withdrawn NCT02456792 Phase 4

Search NIH Clinical Center for Ovarian Hyperstimulation Syndrome

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: ovarian hyperstimulation syndrome

Genetic Tests for Ovarian Hyperstimulation Syndrome

Genetic tests related to Ovarian Hyperstimulation Syndrome:

# Genetic test Affiliating Genes
1 Ovarian Hyperstimulation Syndrome 30 FSHR

Anatomical Context for Ovarian Hyperstimulation Syndrome

MalaCards organs/tissues related to Ovarian Hyperstimulation Syndrome:

42
Ovary, Endothelial, Pituitary, Kidney, Bone, Testes, Skin

Publications for Ovarian Hyperstimulation Syndrome

Articles related to Ovarian Hyperstimulation Syndrome:

(show top 50) (show all 1244)
# Title Authors Year
1
Functioning gonadotroph adenoma with severe ovarian hyperstimulation syndrome: A new emergency in pituitary adenoma surgery? Surgical considerations and literature review. ( 30825998 )
2019
2
Rare genetic variants potentially involved in ovarian hyperstimulation syndrome. ( 30483911 )
2019
3
Lifesaving dose increment of cabergoline in life-threatening spontaneous ovarian hyperstimulation syndrome resistant to all interventions. ( 30560702 )
2019
4
Acute Kidney Injury Due to Ovarian Hyperstimulation Syndrome. ( 30600106 )
2019
5
Luteal phase support with GnRH agonist does not eliminate the risk for ovarian hyperstimulation syndrome. ( 30614333 )
2019
6
In Vitro Maturation of Oocytes in Women at Risk of Ovarian Hyperstimulation Syndrome-A Prospective Multicenter Cohort Study. ( 30644243 )
2019
7
Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial. ( 30684970 )
2019
8
Association of IL-17 and IL-23 follicular fluid concentrations and gene expression profile in cumulus cells from infertile women at risk for ovarian hyperstimulation syndrome. ( 30714434 )
2019
9
Intrafollicular melatonin concentration is elevated in patients with ovarian hyperstimulation syndrome (OHSS) and can serve as an important predictor of OHSS. ( 30725184 )
2019
10
A case report of an abnormal trend in hCG levels in a pregnancy complicated by ovarian hyperstimulation syndrome. ( 30733923 )
2019
11
Life-threatening complications among women with severe ovarian hyperstimulation syndrome. ( 30742828 )
2019
12
Causes of Massive Vulvar Edema in Patients with Severe Ovarian Hyperstimulation Syndrome: A Case Report and Literature Review. ( 30796195 )
2019
13
Oligosypthomatic ovarian hyperstimulation syndrome in a spontaneous uneventful pregnancy. A case report. ( 30806108 )
2019
14
What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model? ( 30892121 )
2019
15
Effect of low-dose aspirin on the development of ovarian hyperstimulation syndrome and outcomes of assisted reproductive techniques in the women with PCOS, a randomized double-blinded clinical trial. ( 30910149 )
2019
16
Inferring biallelism of two FSH receptor mutations associated with spontaneous ovarian hyperstimulation syndrome by evaluating FSH, LH and HCG cross-activity. ( 30910395 )
2019
17
Unusual ultrasonographic finding of ovarian hyperstimulation syndrome in a preterm newborn with severe intra-uterine growth retardation. ( 30924252 )
2019
18
Ovarian hyperstimulation syndrome. A new look at an old problem. ( 30935259 )
2019
19
Clinical characteristics of preterm ovarian hyperstimulation syndrome: seven cases from China and 14 cases from the literature. ( 30957580 )
2019
20
The effect of luteal GnRH antagonist on moderate and severe early ovarian hyperstimulation syndrome during in vitro fertilization treatment: a prospective cohort study. ( 31004220 )
2019
21
A Second Dose of GnRHa in Combination with Luteal GnRH Antagonist May Eliminate Ovarian Hyperstimulation Syndrome in Women with ≥30 Follicles Measuring ≥11 mm in Diameter on Trigger Day and/or Pre-trigger Peak Estradiol Exceeding 10 000 pg/mL. ( 31016522 )
2019
22
Can a cyclooxygenase inhibitor be an option for treatment of ovarian hyperstimulation syndrome? ( 31040646 )
2019
23
Unsuspected adverse effect of albumin in severe ovarian hyperstimulation syndrome: a case report. ( 31058477 )
2019
24
Ovarian hyperstimulation syndrome: A review for emergency clinicians. ( 31097257 )
2019
25
Laparoscopic detorsion of the ovary in ovarian hyperstimulation syndrome during the sixth week of gestation: A case report and review. ( 31103953 )
2019
26
Substantial Effect of Fenugreek Seeds Aqueous Extract on Serum Estradiol Level in Ovarian Hyperstimulation Syndrome Rat Model. ( 31110632 )
2019
27
Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles. ( 30713022 )
2019
28
Higher melatonin in the follicle fluid and MT2 expression in the granulosa cells contribute to the OHSS occurrence. ( 30979376 )
2019
29
An AMH-based FSH dosing algorithm for OHSS risk reduction in first cycle antagonist protocol for IVF/ICSI. ( 31009858 )
2019
30
Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. ( 29055130 )
2018
31
Combined modalities for the prevention of ovarian hyperstimulation syndrome following an excessive response to stimulation. ( 29057693 )
2018
32
Ovarian hyperstimulation syndrome induced by hormone therapy for breast cancer treatment. ( 29061360 )
2018
33
Unilateral pleural effusion as the sole clinical presentation of severe ovarian hyperstimulation syndrome: a systematic review. ( 29063807 )
2018
34
A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols. ( 29086322 )
2018
35
GnRHa trigger and luteal coasting: a new approach for the ovarian hyperstimulation syndrome high-risk patient? ( 29102428 )
2018
36
Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome. ( 29105961 )
2018
37
Correction to: Irani et al., Unilateral pleural effusion as the sole clinical presentation of severe ovarian hyperstimulation syndrome: a systematic review. ( 29140149 )
2018
38
Author Correction: A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols. ( 29178020 )
2018
39
Elective frozen-thawed embryo transfer (FET) in women at risk for ovarian hyperstimulation syndrome. ( 29279182 )
2018
40
Comparison of Cabergoline and Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection. ( 29334199 )
2018
41
Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome. ( 29334275 )
2018
42
Severe ovarian hyperstimulation syndrome: Can we eliminate it through a multipronged approach? ( 29386731 )
2018
43
Ureteral obstruction and ruptured kidney following ovarian hyperstimulation syndrome. ( 29391290 )
2018
44
Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment. ( 29446481 )
2018
45
Effects of electroacupuncture on luteal regression and steroidogenesis in ovarian hyperstimulation syndrome model rat. ( 29482802 )
2018
46
Multiorgan failure associated with severe ovarian hyperstimulation syndrome due to inadequate protocol optimisation: a rare but avoidable complication. ( 29507026 )
2018
47
The Ovarian Hyperstimulation Syndrome. ( 29544639 )
2018
48
Is thromboprophylaxis cost effective in ovarian hyperstimulation syndrome: A systematic review and cost analysis. ( 29602141 )
2018
49
Ovarian hyperstimulation syndrome leading to ventriculoperitoneal shunt malfunction: Case report. ( 29655999 )
2018
50
Ascites Index - a novel technique to evaluate ascites in ovarian hyperstimulation syndrome: a concept-proof study. ( 29781072 )
2018

Variations for Ovarian Hyperstimulation Syndrome

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Hyperstimulation Syndrome:

76
# Symbol AA change Variation ID SNP ID
1 FSHR p.Thr449Ile VAR_017244 rs28928870
2 FSHR p.Asp567Asn VAR_017245 rs28928871
3 FSHR p.Ser128Tyr VAR_039279
4 FSHR p.Thr449Ala VAR_039282
5 FSHR p.Ile545Thr VAR_039284
6 FSHR p.Met512Ile VAR_074535
7 FSHR p.Val514Ala VAR_074536
8 FSHR p.Ala575Val VAR_074537

ClinVar genetic disease variations for Ovarian Hyperstimulation Syndrome:

6 (show top 50) (show all 62)
# Gene Variation Type Significance SNP ID Assembly Location
1 FSHR NM_000145.3(FSHR): c.919G> A (p.Ala307Thr) single nucleotide variant Benign rs6165 GRCh37 Chromosome 2, 49191041: 49191041
2 FSHR NM_000145.3(FSHR): c.919G> A (p.Ala307Thr) single nucleotide variant Benign rs6165 GRCh38 Chromosome 2, 48963902: 48963902
3 FSHR NM_000145.3(FSHR): c.2039G> A (p.Ser680Asn) single nucleotide variant Benign rs6166 GRCh37 Chromosome 2, 49189921: 49189921
4 FSHR NM_000145.3(FSHR): c.2039G> A (p.Ser680Asn) single nucleotide variant Benign rs6166 GRCh38 Chromosome 2, 48962782: 48962782
5 FSHR NM_000145.3(FSHR): c.1346C> T (p.Thr449Ile) single nucleotide variant Pathogenic rs28928870 GRCh37 Chromosome 2, 49190614: 49190614
6 FSHR NM_000145.3(FSHR): c.1346C> T (p.Thr449Ile) single nucleotide variant Pathogenic rs28928870 GRCh38 Chromosome 2, 48963475: 48963475
7 FSHR NM_000145.3(FSHR): c.1699G> A (p.Asp567Asn) single nucleotide variant Pathogenic rs28928871 GRCh37 Chromosome 2, 49190261: 49190261
8 FSHR NM_000145.3(FSHR): c.1699G> A (p.Asp567Asn) single nucleotide variant Pathogenic rs28928871 GRCh38 Chromosome 2, 48963122: 48963122
9 FSHR NM_000145.3(FSHR): c.1345A> G (p.Thr449Ala) single nucleotide variant Pathogenic rs121909663 GRCh37 Chromosome 2, 49190615: 49190615
10 FSHR NM_000145.3(FSHR): c.1345A> G (p.Thr449Ala) single nucleotide variant Pathogenic rs121909663 GRCh38 Chromosome 2, 48963476: 48963476
11 FSHR NM_000145.3(FSHR): c.1634T> C (p.Ile545Thr) single nucleotide variant Pathogenic rs121909664 GRCh37 Chromosome 2, 49190326: 49190326
12 FSHR NM_000145.3(FSHR): c.1634T> C (p.Ile545Thr) single nucleotide variant Pathogenic rs121909664 GRCh38 Chromosome 2, 48963187: 48963187
13 FSHR NM_000145.3(FSHR): c.383C> A (p.Ser128Tyr) single nucleotide variant Pathogenic rs121909665 GRCh37 Chromosome 2, 49217768: 49217768
14 FSHR NM_000145.3(FSHR): c.383C> A (p.Ser128Tyr) single nucleotide variant Pathogenic rs121909665 GRCh38 Chromosome 2, 48990629: 48990629
15 FSHR NM_000145.3(FSHR): c.-29G> A single nucleotide variant Benign rs1394205 GRCh37 Chromosome 2, 49381585: 49381585
16 FSHR NM_000145.3(FSHR): c.-29G> A single nucleotide variant Benign rs1394205 GRCh38 Chromosome 2, 49154446: 49154446
17 FSHR NM_000145.3(FSHR): c.24G> T (p.Leu8Phe) single nucleotide variant Likely benign rs115030945 GRCh38 Chromosome 2, 49154394: 49154394
18 FSHR NM_000145.3(FSHR): c.24G> T (p.Leu8Phe) single nucleotide variant Likely benign rs115030945 GRCh37 Chromosome 2, 49381533: 49381533
19 FSHR NM_000145.3(FSHR): c.*256C> T single nucleotide variant Likely benign rs72873077 GRCh38 Chromosome 2, 48962477: 48962477
20 FSHR NM_000145.3(FSHR): c.*256C> T single nucleotide variant Likely benign rs72873077 GRCh37 Chromosome 2, 49189616: 49189616
21 FSHR NM_000145.3(FSHR): c.1576T> C (p.Leu526=) single nucleotide variant Uncertain significance rs138281715 GRCh38 Chromosome 2, 48963245: 48963245
22 FSHR NM_000145.3(FSHR): c.1576T> C (p.Leu526=) single nucleotide variant Uncertain significance rs138281715 GRCh37 Chromosome 2, 49190384: 49190384
23 FSHR NM_000145.3(FSHR): c.446+10T> C single nucleotide variant Likely benign rs200504733 GRCh38 Chromosome 2, 48990556: 48990556
24 FSHR NM_000145.3(FSHR): c.446+10T> C single nucleotide variant Likely benign rs200504733 GRCh37 Chromosome 2, 49217695: 49217695
25 FSHR NM_000145.3(FSHR): c.373C> A (p.Leu125Met) single nucleotide variant Uncertain significance rs886056151 GRCh38 Chromosome 2, 49017490: 49017490
26 FSHR NM_000145.3(FSHR): c.373C> A (p.Leu125Met) single nucleotide variant Uncertain significance rs886056151 GRCh37 Chromosome 2, 49244629: 49244629
27 FSHR NM_000145.3(FSHR): c.*563T> C single nucleotide variant Likely benign rs80295823 GRCh38 Chromosome 2, 48962170: 48962170
28 FSHR NM_000145.3(FSHR): c.*563T> C single nucleotide variant Likely benign rs80295823 GRCh37 Chromosome 2, 49189309: 49189309
29 FSHR NM_000145.3(FSHR): c.*199A> G single nucleotide variant Uncertain significance rs886056148 GRCh38 Chromosome 2, 48962534: 48962534
30 FSHR NM_000145.3(FSHR): c.*199A> G single nucleotide variant Uncertain significance rs886056148 GRCh37 Chromosome 2, 49189673: 49189673
31 FSHR NM_000145.3(FSHR): c.1831C> G (p.Leu611Val) single nucleotide variant Uncertain significance rs886056149 GRCh38 Chromosome 2, 48962990: 48962990
32 FSHR NM_000145.3(FSHR): c.1831C> G (p.Leu611Val) single nucleotide variant Uncertain significance rs886056149 GRCh37 Chromosome 2, 49190129: 49190129
33 FSHR NM_000145.3(FSHR): c.688A> G (p.Ile230Val) single nucleotide variant Uncertain significance rs367711694 GRCh38 Chromosome 2, 48968864: 48968864
34 FSHR NM_000145.3(FSHR): c.688A> G (p.Ile230Val) single nucleotide variant Uncertain significance rs367711694 GRCh37 Chromosome 2, 49196003: 49196003
35 FSHR NM_000145.3(FSHR): c.219G> A (p.Glu73=) single nucleotide variant Uncertain significance rs377397067 GRCh38 Chromosome 2, 49068224: 49068224
36 FSHR NM_000145.3(FSHR): c.219G> A (p.Glu73=) single nucleotide variant Uncertain significance rs377397067 GRCh37 Chromosome 2, 49295363: 49295363
37 FSHR NM_000145.3(FSHR): c.-58T> C single nucleotide variant Uncertain significance rs886056153 GRCh38 Chromosome 2, 49154475: 49154475
38 FSHR NM_000145.3(FSHR): c.-58T> C single nucleotide variant Uncertain significance rs886056153 GRCh37 Chromosome 2, 49381614: 49381614
39 FSHR NM_000145.3(FSHR): c.*111T> C single nucleotide variant Likely benign rs140106399 GRCh38 Chromosome 2, 48962622: 48962622
40 FSHR NM_000145.3(FSHR): c.*111T> C single nucleotide variant Likely benign rs140106399 GRCh37 Chromosome 2, 49189761: 49189761
41 FSHR NM_000145.3(FSHR): c.1596G> A (p.Met532Ile) single nucleotide variant Uncertain significance rs757909841 GRCh38 Chromosome 2, 48963225: 48963225
42 FSHR NM_000145.3(FSHR): c.1596G> A (p.Met532Ile) single nucleotide variant Uncertain significance rs757909841 GRCh37 Chromosome 2, 49190364: 49190364
43 FSHR NM_000145.3(FSHR): c.1030G> C (p.Val344Leu) single nucleotide variant Uncertain significance rs772756688 GRCh38 Chromosome 2, 48963791: 48963791
44 FSHR NM_000145.3(FSHR): c.1030G> C (p.Val344Leu) single nucleotide variant Uncertain significance rs772756688 GRCh37 Chromosome 2, 49190930: 49190930
45 FSHR NM_000145.3(FSHR): c.947A> G (p.Glu316Gly) single nucleotide variant Uncertain significance rs886056150 GRCh38 Chromosome 2, 48963874: 48963874
46 FSHR NM_000145.3(FSHR): c.947A> G (p.Glu316Gly) single nucleotide variant Uncertain significance rs886056150 GRCh37 Chromosome 2, 49191013: 49191013
47 FSHR NM_000145.3(FSHR): c.*246T> A single nucleotide variant Likely benign rs72825259 GRCh38 Chromosome 2, 48962487: 48962487
48 FSHR NM_000145.3(FSHR): c.*246T> A single nucleotide variant Likely benign rs72825259 GRCh37 Chromosome 2, 49189626: 49189626
49 FSHR NM_000145.3(FSHR): c.1330G> A (p.Ala444Thr) single nucleotide variant Uncertain significance rs202162496 GRCh38 Chromosome 2, 48963491: 48963491
50 FSHR NM_000145.3(FSHR): c.1330G> A (p.Ala444Thr) single nucleotide variant Uncertain significance rs202162496 GRCh37 Chromosome 2, 49190630: 49190630

Expression for Ovarian Hyperstimulation Syndrome

Search GEO for disease gene expression data for Ovarian Hyperstimulation Syndrome.

Pathways for Ovarian Hyperstimulation Syndrome

Pathways related to Ovarian Hyperstimulation Syndrome according to KEGG:

38
# Name Kegg Source Accession
1 Neuroactive ligand-receptor interaction hsa04080

GO Terms for Ovarian Hyperstimulation Syndrome

Cellular components related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 ALB AMH CGA F5 GNRH1 REN
2 extracellular region GO:0005576 9.23 ALB AMH CGA F5 GNRH1 KDR
3 platelet alpha granule lumen GO:0031093 9.13 ALB F5 VEGFA

Biological processes related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.86 ALB GNRH1 KDR VEGFA
2 regulation of signaling receptor activity GO:0010469 9.8 AMH CGA GNRH1 VEGFA
3 positive regulation of angiogenesis GO:0045766 9.65 CDH5 KDR VEGFA
4 cell maturation GO:0048469 9.58 REN VEGFA
5 platelet degranulation GO:0002576 9.58 ALB F5 VEGFA
6 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.57 KDR VEGFA
7 activation of adenylate cyclase activity GO:0007190 9.55 FSHR LHCGR
8 positive regulation of focal adhesion assembly GO:0051894 9.54 KDR VEGFA
9 male gonad development GO:0008584 9.54 FSHR LHCGR REN
10 female gonad development GO:0008585 9.52 CYP19A1 FSHR
11 cell migration involved in sprouting angiogenesis GO:0002042 9.51 KDR VEGFA
12 uterus development GO:0060065 9.46 CYP19A1 FSHR
13 vascular endothelial growth factor signaling pathway GO:0038084 9.43 KDR VEGFA
14 positive regulation of positive chemotaxis GO:0050927 9.32 KDR VEGFA
15 ovulation cycle process GO:0022602 9.26 FSHR LHCGR
16 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.16 KDR VEGFA
17 hormone-mediated signaling pathway GO:0009755 9.13 FSHR LHCGR REN
18 gonad development GO:0008406 8.8 AMH CGA FSHR

Molecular functions related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxygen binding GO:0019825 9.16 ALB CYP19A1
2 hormone activity GO:0005179 9.13 AMH CGA GNRH1
3 protein-hormone receptor activity GO:0016500 8.62 FSHR LHCGR

Sources for Ovarian Hyperstimulation Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....